Inveltys now available in US

Kala Pharmaceuticals has launched its twice-daily ocular corticosteroid Inveltys in the United States, according to a press release.
Inveltys (loteprednol etabonate ophthalmic suspension 1%), which uses Kala’s Ampplify mucus-penetrating particle drug delivery technology to enhance penetration into target tissues, is indicated for the treatment of postoperative inflammation and pain after ocular surgery.
The company has hired a specialty sales force of 57 territory sales managers, the release said.
“Formulary contract bids are in discussion for commercial insurance coverage in 2019

Full Story →